Enanta Pharmaceuticals (ENTA) Non-Current Deffered Revenue (2012 - 2019)
Enanta Pharmaceuticals (ENTA) posted Non-Current Deffered Revenue of $900000.0 for Q3 2019, down 2.49% on a QoQ basis from $923000.0 in Q2 2019, and up 51.77% year-over-year from $593000.0 in Q3 2018.
Enanta Pharmaceuticals (ENTA) Non-Current Deffered Revenue (2012 - 2019) Analysis & Trends
Enanta Pharmaceuticals' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $900000.0 for Q3 2019.
- Quarterly Non-Current Deffered Revenue rose 51.77% year-over-year to $900000.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $900000.0 (up 51.77% YoY) and the FY2019 annual result came in at $900000.0, up 51.77% from the prior year.
- Non-Current Deffered Revenue was $900000.0 for Q3 2019 at Enanta Pharmaceuticals, down from $923000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $923000.0 in Q2 2019 and bottomed at $161000.0 in Q1 2015.
- A 5-year average of $650789.5 and a median of $674000.0 in 2018 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2015 — Non-Current Deffered Revenue jumped 322.22% — and 2018, when it dropped 14.06%.
- Enanta Pharmaceuticals' Non-Current Deffered Revenue stood at $646000.0 in 2015, then advanced by 8.51% to $701000.0 in 2016, then slipped by 6.7% to $654000.0 in 2017, then increased by 3.06% to $674000.0 in 2018, then surged by 33.53% to $900000.0 in 2019.
- Business Quant data shows ENTA's Non-Current Deffered Revenue at $900000.0 in Q3 2019, $923000.0 in Q2 2019, and $842000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 900,000.00 |
| Jun 30, 2019 | 923,000.00 |
| Mar 31, 2019 | 842,000.00 |
| Dec 31, 2018 | 674,000.00 |
| Sep 30, 2018 | 593,000.00 |
| Jun 30, 2018 | 611,000.00 |
| Mar 31, 2018 | 632,000.00 |
| Dec 31, 2017 | 654,000.00 |
| Sep 30, 2017 | 676,000.00 |
| Jun 30, 2017 | 711,000.00 |
| Mar 31, 2017 | 706,000.00 |
| Dec 31, 2016 | 701,000.00 |
| Sep 30, 2016 | 696,000.00 |
| Jun 30, 2016 | 682,000.00 |
| Mar 31, 2016 | 664,000.00 |
| Dec 31, 2015 | 646,000.00 |
| Sep 30, 2015 | 628,000.00 |
| Jun 30, 2015 | 265,000.00 |
| Mar 31, 2015 | 161,000.00 |
| Dec 31, 2014 | 153,000.00 |